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Background: Vandetanib is the most largely used tyrosine kinase inhibitor (TKI) in 
patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, 
we conducted a systematic review on its efficacy and attempted to perform a meta- 
analysis adopting standardized RECIST criteria as end-points.
methods: The terms “medullary thyroid” and “protein kinase inhibitor” (then including all 
TKIs) were searched in PubMed, ClinicalTrials.gov, and CENTRAL. Only original studies 
reporting the use of Vandetanib as single agent in MTC were included. The last search 
was performed on October 31, 2017 and registered in PROSPERO on December 12, 
2017 (n = CRD42017081537).
Results: The search revealed 487 articles, and, after removing duplicates, reading title 
and abstract, and screening the eligible papers, 10 studied were finally included. Two 
papers were randomized controlled trials and eight were observational longitudinal 
studies. No data were available for overall survival. No heterogeneity nor publication 
bias were recorded in the pooled rate of complete response (0.7%) and stable disease 
(47%). Mild to moderate heterogeneity were recorded in the pooled rate of other end-
points. Data of the studies did not allow to perform a meta-analysis of time-to-event 
outcomes.
conclusion: Vandetanib should be considered as a promising treatment in advanced 
MTC. However, data based on RECIST endpoints do not currently provide high-level 
evidence on its efficacy.
Keywords: medullary thyroid carcinoma, tyrosine kinase inhibitors, vandetanib, ReciSt, systematic review, meta-
analysis
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iNtRODUctiON
Rationale
Medullary thyroid carcinoma (MTC) is a thyroid tumor which 
can occur as hereditary (20% of cases), due to an activating 
germline mutation of the REarranged during Transfection (RET) 
protooncogene, or sporadic (80%), with a somatic RET muta-
tion (1). While the majority of these carcinomas involves only 
the thyroid gland and reaches the complete cure following total 
thyroidectomy, a not negligible rate manifests as locally advanced 
and/or with distant metastases. The latter patients have a poor 
prognosis and need alternative treatments other than surgery. 
Generally, the 10-year overall survival (OS) of patients affected 
by MTC is 95% in patients with local disease, while this rate 
decreases to 75% in those with regional invasion and 40% in the 
presence of distant metastases (2).
Objectives
Cytotoxic chemotherapy and external beam radiation therapy 
are poorly effective for metastatic MTC. For this reason, current 
guidelines support the use of tyrosine kinase inhibitors (TKIs) 
as first-line therapy in patients with significant tumor burden 
and symptomatic or progressive metastatic disease according to 
RECIST criteria (1). The pathophysiology of this type of tumor 
and the therapeutic approaches have been studied also by the use 
of animal models of MTC (3). Vandetanib is the most largely used 
TKI in advanced MTC, targeting the RET oncogene, the vascular 
endothelial growth factor receptor, and the epidermal growth fac-
tor receptor (4). Following Phase I and II trials, in 2006, the Phase 
III ZETA randomized clinical trial (RCT) started, based on their 
results, Vandetanib was eventually approved by the Food and 
Drug Administration (FDA) for the treatment of symptomatic or 
progressive MTC in patients with unresectable, locally advanced 
or metastatic disease in 2011 (5). Notably, TKIs are frequently 
associated with severe side effects, and this could be a significant 
limitation for their chronic use. Furthermore, the discontinua-
tion of a TKI treatment may represent a boost for rapid increase 
of tumor growth and disease progression (6–8). Thus, whether 
to treat or not a patient with advanced MTC with TKI may be 
a difficult decision, and a patient-tailored approach is recom-
mended. MTC is a rare tumor, and this limits our knowledge on 
the efficacy of TKI in these cancers due to the inherent difficulty 
in collecting adequate samples for statistical analysis.
Research Question
Here, we have conducted a systematic review on the efficacy of 
Vandetanib in the treatment of locally advanced and/or metastatic 
MTC, attempting to perform a meta-analysis with the adoption of 
standardized RECIST criteria as endpoints (9, 10).
metHODS
Study Design
The study design included studies investigating the efficacy of 
Vandetanib in MTC patients in terms of RECIST criteria. The 
present systematic review was registered on December 12, 
2017 in PROSPERO (n = CRD42017081537) and performed in 
accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement. The PRISMA 
checklist can be found in Table S1 in Supplementary Material.
Participants, interventions, and 
comparators
Participants were MTC patients treated with Vandetanib due to 
advanced disease. There was no comparator.
Search Strategy
To retrieve the best of published literature on the efficacy of 
Vandetanib in MTC, a four-step search strategy was planned. 
First, we identified keywords and MeSH terms in PubMed. 
Second, the terms “medullary thyroid” and “protein kinase 
inhibitor” (then including all TKIs) were searched in PubMed, 
ClinicalTrials.gov, and CENTRAL. Third, according to our aim, 
original studies reporting on the use of Vandetanib as a single 
agent in patients with locally advanced or metastatic MTC were 
included for the present analysis. Fourth, references of included 
studies were searched for additional papers on the same topic. 
The last search was performed on October 31, 2017. No language 
restrictions were adopted. Articles with unclear data, case reports, 
and series with overlapping results were excluded. Two investiga-
tors (Marco Castellana and Pierpaolo Trimboli) independently 
searched papers, screened titles, and abstracts of the retrieved 
articles, reviewed the full-texts, and selected articles for their final 
inclusion.
Data Sources, Studies Sections, and Data 
extraction
The same two investigators (Marco Castellana and Pierpaolo 
Trimboli) extracted data independently and in duplicate and in a 
piloted form. The following data were reported: 1. general infor-
mation on the study (first author or principal investigator, year 
of publication, study name, study type and phase, study fund-
ing, drug in active treatment and comparator arms, duration of 
treatment, listed location countries, number and characteristics 
of patients, such as age, gender, hereditary/sporadic MTC, their 
previous treatments); 2. endpoints according to RECIST, includ-
ing complete response (CR), partial response (PR), stable disease 
(SD), progressive disease (PD), objective response rate (ORR), 
disease control rate (DCR), progression-free survival (PFS), OS, 
time to response (TTR), duration of response (DOR), and PD 
as reason for discontinuation. Discrepancies were solved by a 
mutual consensus among all authors.
Data analysis
For CR, PR, SD, PD, ORR, DCR, and PD as reason for dis-
continuation, a proportion meta-analysis was performed; the 
number of patients with a specific endpoint was extracted from 
the paper or calculated from the frequency reported in the text. 
In addition, data on SD at 6, 12, 24, and 36 months, respectively, 
were searched. For time-to-event outcomes (OS, PFS, TTR, and 
DOR), a log-rank analysis was attempted. For statistical pooling 
of the data, the fixed method was used. Pooled data are presented 
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FigURe 1 | Flowchart of the study selection process.
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with 95% confidence intervals (95% CI) and displayed using a 
Forest plot, when possible. I2 index was used to quantify the 
heterogeneity among the studies, a significant heterogeneity 
being defined as an I2 value >50%. Egger’s test was also carried 
out to evaluate the presence of significant publication bias, and a 
p value <0.05 identified the presence of bias. Statistical analyses 
were performed using the StatsDirect statistical software version 
(StatsDirect Ltd., Altrincham, UK).
ReSULtS
Study Selection and characteristics
The search revealed 487 potentially relevant articles. After dupli-
cates removal, 478 were initially selected, and by reading their 
title and abstract 450 studies were excluded. The full-text of the 
remaining 28 papers was obtained and evaluated; 18 articles were 
excluded because of several reasons (i.e., the patients received a 
TKI other than Vandetanib, Vandetanib was associated with a 
proteasome inhibitor in the active treatment arm, or no data use-
ful for the meta-analysis were reported). Finally, 10 studies were 
included in the present systematic review (11–20) (Figure 1).
Synthesized analysis
The characteristics of the included articles are summarized in 
Table  1. The studies were published between 2010 and 2017, 
and reported cohorts of 14–331 MTC patients. Two studies were 
RCTs, eight were observational longitudinal studies (OLSs); five 
studies were Phase II OLSs, single-country and single-arm. Five 
studies were sponsored by industry. Participants were outpatients 
diagnosed with histologically confirmed, unresectable, locally 
advanced, or metastatic MTC. Three studies included children and 
adolescents. A total of 496 patients were treated with Vandetanib 
in these 10 studies; 100 patients were given placebo in only 1 RCT. 
One RCT compared the effects of two doses of Vandetanib, i.e., 
150 and 300 mg/day. The mean age was 51.2 ± 6.8 years, 56.1% 
of the patients were male, 24.8% were hereditary MTC, 95.5% 
FigURe 2 | Forest plot of data on complete response (fixed effect).
taBLe 2 | Data available in the included studies and extracted from the meta-analysis.
Reference PFS OS cR PR SD PD ORR DcR ttR DOR PD as reason for discontinuation 
of vandetanib
Robinson et al. (11) Yes No Yes Yes Yes Yes Yes Yes No No Yes
Wells et al. (12) Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes
Wells et al. (13) Yes No Yes Yes Yes Yes Yes Yes No Yes Yes
Fox et al. (14) No No Yes Yes Yes Yes Yes Yes No No Yes
Chougnet et al. (15) Yes No Yes Yes Yes Yes Yes Yes No No Yes
Akshintala et al. (16) No No Yes Yes Yes Yes Yes Yes Yes No No
No author listed, 2016 (17) No No Yes Yes Yes Yes Yes Yes Yes Yes No
Tiedje et al. (18) Yes No Yes Yes Yes Yes Yes Yes No No No
Uchino et al. (19) No No Yes Yes Yes Yes Yes Yes No No Yes
Werner et al. (20) No No Yes Yes Yes Yes Yes Yes No No No
CR, complete response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free 
survival; PR, partial response; SD, stable disease; TTR, time to response.
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had distant metastases. The median duration of treatment ranged 
from 8.7 to 39.2  months. Among Vandetanib-treated patients, 
the median PFS ranged from 7 to 30.5 months (finding from five 
studies), TTR from 4.3 to 18.6 months (three studies), and DOR 
from 10.2 to 22.2 months (three studies). Among placebo-treated, 
a PFS of 19.3 and a DOR of 16.3 months were reported [in one 
study (13)].
Data of RECIST endpoints available for the meta-analyses 
are detailed in Table 2. Remarkably, no data were available on 
OS; among other endpoints, CR, PR, SD, PD, ORR, and DCR 
were reported in all included studies, while PD as reason for 
discontinuation in six of them. No heterogeneity nor publica-
tion bias were recorded in the pooled rate of CR (0.7%) and 
SD (47%) (Figures  2 and 3). Data on the rate of SD during 
the study (i.e., at 6, 12, or 24  months) were reported in few 
studies, and thus we were not able to perform a meta-analysis 
on this endpoint. No publication bias and mild-to-moderate 
heterogeneity were recorded in the pooled rate of the other 
end-points (Table  3). Data on the included studies did not 
allow us to perform a meta-analysis on time-to-event out-
comes (PFS, TTR, and DOR) because only one study included 
a placebo arm (13).
DiScUSSiON
Summary of Findings
The aim of the current review was to identify the best avail-
able evidence on the efficacy of Vandetanib in treating locally 
advanced or metastatic MTC. Indeed, Vandetanib is currently 
the most largely used TKI for advanced MTC. To the best of our 
knowledge, this is the first systematic review and meta-analysis 
on this topic focusing on the RECIST criteria as benchmark. 
FigURe 3 | Forest plot of data on stable disease (fixed effect).
taBLe 3 | Results of meta-analysis of RECIST endpoints.
Pooled rate [95% confidence intervals (95% ci)] I2 index (95% ci) egger’s test (95% ci) p
Complete response 0.07% (0.007–0.2) 0% (0–53) 0.14 (−0.15 to 0.44) 0.296
Stable disease 47% (42–51) 45% (0–72) 0.47 (−1.69 to 2.63) 0.628
Objective response rate 35% (31–40) 71% (33–83) −0.51 (−3.52 to 2.48) 0.701
Disease control rate 83% (80–86) 69% (27–82) −0.98 (−3.66 to 1.70) 0.422
Partial response 35% (31–40) 73% (40–84) 0.33 (0.24–0.43) 0.755
Progressive disease (PD) 14% (11–17) 61% (1–79) 0.59 (−1.84 to 3.01) 0.593
PD as reason for discontinuation of Vandetanib 30% (26–35) 65% (0–83) −0.7 (−4.91 to 3.50) 0.685
I2 index quantified the heterogeneity among the studies, and a value >50% indicated significant heterogeneity; Egger’s test evaluated the publication bias, identified by a p value 
<0.05.
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Notably, most of the retrieved papers (both original reports and 
reviews) identified by our search strategy focused on the side-
effects, rather than on the efficacy of TKI, and only two RCTs 
and eight OLSs were eligible for inclusion in our analysis. As 
a major result, no analysis could be performed for OS because 
this finding was not reported in any of these 10 articles. The 
pooled CR and SD were the most statistically relevant results; 
less than 1 in 100 MTC patients had a CR to Vandetanib and 
about a half (47%) showed a SD at the end of the study. The 
other dichotomous endpoints presented statistical limitations 
(i.e., significant heterogeneity), while time-to-event outcomes 
could not be meta-analyzed due to the design of the studies.
As mentioned above, OS of MTC patients is significantly 
reduced in the presence of metastases (2). Besides the local 
effects caused by metastases in the liver, bone, lung, and 
mediastinal region, patients with advanced MTC may suffer 
from diarrhea (due to hypercalcitoninemia) or from Cushing’s 
syndrome due to ectopic ACTH or CRH secretion (1). 
Remarkably, TKI treatment might cause side effects, diminish-
ing the patient’s quality of life. The more common adverse 
effects are gastrointestinal (diarrhea, nausea, and decreased 
appetite), cardiovascular (hypertension, QTc prolongation), 
dermatological (acne, skin rash), and general symptoms such 
as fatigue (6). Adverse events may occur in mild or severe 
forms; dose reduction may lead to improvement of side effects 
in mild cases while in severe forms Vandetanib should be inter-
rupted until symptoms improve (7). Since metastatic MTC is 
incurable, it is necessary to consider that usually TKI treat-
ment must be continued chronically, and the above side effects 
may impact on the patients’ quality of life (6). Furthermore, 
the long-term effects of the chronic use of Vandetanib are not 
known (1). Therefore, once metastases have appeared and/or 
there is a local cervical invasion, the clinician must carefully 
identify the best treatment considering the possibility to slow 
tumor progression but also the risk of side effects in the context 
of the best quality of life possible (8). On this ground, recent 
studies are proposing alternative treatments that could lead to 
a more individually tailored treatment (21).
A meta-analysis on TKIs for advanced metastatic thyroid 
cancer, including several cancer types, has been recently published. 
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Six RCTs were included, one of which herein included also (13). 
Higher PFS was reported among Vandetanib- and Cabozantinib-
treated patients with respect to controls (HR =  0.36; 95% CI, 
0.22–0.58) (22). However, since these authors included in their 
meta-analysis studies with different therapies, their results could 
not be compared with those in our meta-analysis.
Limitations
Some potential limitations of our meta-analysis should be 
addressed. According to our search strategy, we could find both 
RCTs and OLSs. The study design of these papers was obviously 
highly different (duration of the study, dose of Vandetanib 
used) and the series included different patient types (i.e., adults/
adolescents, patients previously treated with systemic therapy 
or not, hereditary/sporadic MTC). Also, some studies adopted 
RECIST 1.0 (9) to evaluate the response to therapy, while others 
used the version 1.1 (10). All of these discrepancies might affect 
the herein reported pooled results. On February 2018, then after 
our literature search, an update of NCT00514046 was published 
by Kraft et al. (23); endpoints according to RECIST did not differ 
from the one reported by Akshintala et al. (16).
conclusion
This study demonstrates that a negligible rate of patients with 
advanced MTC treated by Vandetanib has a CR at the end of 
the study and less than a half has SD. Vandetanib, the most 
largely used therapy in advanced MTC, should be considered 
as a promising treatment in these patients. However, data on 
RECIST endpoints to be analyzed are limited, and the overall 
evidence on the efficacy of Vandetanib in advanced MTC should 
thus be considered as low at present. Furthermore, RCTs are 
needed to obtain more robust information, especially in terms 
of OS.
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